Free Trial
LON:VAL

ValiRx (VAL) Share Price, News & Analysis

ValiRx logo
GBX 1.68 0.00 (0.00%)
(As of 11/22/2024 ET)

About ValiRx Stock (LON:VAL)

Key Stats

Today's Range
1.63
1.75
50-Day Range
1.21
2.18
52-Week Range
1.20
13.50
Volume
282,678 shs
Average Volume
1.02 million shs
Market Capitalization
£2.22 million
P/E Ratio
N/A
Dividend Yield
0.63%
Price Target
N/A
Consensus Rating
N/A

Company Overview

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.

Receive VAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter.

VAL Stock News Headlines

ValiRx Secures Funding for Prostate Cancer Research
Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
See More Headlines

VAL Stock Analysis - Frequently Asked Questions

ValiRx's stock was trading at GBX 5.90 at the beginning of the year. Since then, VAL shares have decreased by 71.6% and is now trading at GBX 1.68.
View the best growth stocks for 2024 here
.

ValiRx plc (LON:VAL) posted its quarterly earnings data on Monday, September, 7th. The company reported ($4.43) EPS for the quarter.

Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Lloyds Banking Group (LLOY), IQE (IQE) and Scirocco Energy Plc (SOLO.L) (SOLO).

Company Calendar

Last Earnings
9/07/2020
Today
11/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Petroleum And Natural Gas
CIK
N/A
Fax
N/A
Employees
5,450
Year Founded
N/A

Profitability

Net Income
£-1,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 0.03 per share
Book Value
GBX 3 per share

Miscellaneous

Free Float
N/A
Market Cap
£2.22 million
Optionable
Not Optionable
Beta
0.59
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (LON:VAL) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners